Delivery Order SPE2DB22D2206-SPE2DB25FJC54
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $11,500.66, is scheduled for completion by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $1,185.69. This is a firm fixed price delivery order under a non-set-aside competitive procurement. The contract is set to be completed by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for supply of HUMIRA (CF) Pen 40 mg/0.4 mls with a ceiling value of $30,231.93. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract with an ultimate completion date of July 29, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill the performance...
- The Defense Logistics Agency awarded a $43,110.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with final delivery required by July 15, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 1, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mL, a biologic medication used to treat inflammatory conditions. This competitively awarded, firm fixed-price delivery order has a ceiling value of $1,079.62 and is scheduled for completion by July 2, 2025. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,965.62 on April 24, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, a prescription pharmaceutical product used to treat inflammatory conditions. This firm fixed-price contract, which is scheduled for completion by April 25, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a $1,888.25 delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency's Medical Supply Chain has awarded a delivery order valued at $7,810.81 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. The contract, issued on September 15, 2025, with an ultimate completion date of September 16, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will take...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product commonly used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $5,023.14, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJC54Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used to treat inflammatory conditions. This competitively awarded, firm fixed-price delivery order has a ceiling value of $25,380.93 and is scheduled for completion by July 29, 2025. The contract utilizes no set-aside designations and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills a critical role in supporting federal medical procurement for military and veteran healthcare systems. Through its DLA prime contract vehicle, the company supplies a comprehensive portfolio of pharmaceutical products and medical supplies to support Defense Health Agency programs and other government healthcare entities worldwide. This delivery order exemplifies the company's ongoing role as a primary vendor for specialty medications and brand-name pharmaceuticals essential to military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.4k | 7/28/25 |